Corvus Pharmaceuticals Inc (CRVS)vsInsmed Inc (INSM)
CRVS
Corvus Pharmaceuticals Inc
$13.15
-4.36%
HEALTHCARE · Cap: $1.12B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
CRVS leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CRVS
Avoid22
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Trading at 16.0x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CRVS
The strongest argument for CRVS centers on Debt/Equity.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CRVS
The primary concerns for CRVS are Price/Book, Revenue Growth, EPS Growth.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CRVS profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
CRVS generates stronger free cash flow (-9M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Corvus Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?